Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children

LYMPHOID TUMORS , ,

NA Batmanova, MA Shervashidze, AV Popa, LYu Grivtsova, IN Serebryakova, GL Mentkevich

NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478

For correspondence: Natal’ya Andreevna Batmanova, 24 Kashirskoye sh., Moscow, Russian Federation, 115478; Tel.: +7(925)321-26-42; e-mail: Batmanova_nataly@mail.ru

For citation: Batmanova NА, Shervashidze MА, Popa АV, et al. Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children. Clinical oncohematology. 2017;10(3):381–9 (In Russ).

DOI: 10.21320/2500-2139-2017-10-3-381-389

ABSTRACT

Background & Aims. Despite significant success in the treatment of acute lymphoblastic leukemia (ALL) in children, relapses and drug resistance to the standard therapy remain the main cause of treatment failure. The addition of bortezomib to the combination therapy of relapsed ALL to change the sensitivity of blast cells may be a perspective approach to cure patients. The aim was to evaluate the efficacy and toxicity of the anti-relapse ALL treatment protocols REZ BFM 95/96 without bortezomib and COG AALL07P1 with bortezomib in relapsed and refractory ALL in children.

Materials & Methods. The study included 54 children with a confirmed ALL of various localizations. From 1995 to 2011, ALL REZ BFM 95/96 treatment without bortezomib was administered to 26 patients. From 2011 to 2016, 28 children received COG AALL07P1 combination treatment with bortezomib.

Results. The immediate treatment efficacy significantly higher in patients treated with bortezomib (85.7 % vs 57.6 %) after induction chemotherapy with the ALL REZ BFM 95/96. The analysis of the long-term outcomes (disease-free, event-free, overall survival) showed no significant differences between the groups. The event-free survival of patients with isolated bone marrow relapses for a period of 2 years was 20.3 ± 17.5 %. The tolerability of the program was acceptable, complications developing during myelosuppression were not associated with the administration of bortezomib.

Conclusion. The intensification of induction chemotherapy in recurrent remission according to COG AALL07P1 protocol with the addition of bortezomib allowed to increase the number of complete remissions including MRD negative ones.

Keywords: acute lymphoblastic leukemia, refractoriness, relapses, bortezomib.

Received: February 24, 2017

Accepted: May 2, 2017

Read in PDF (RUS)pdficon

REFERENCES

  1. Менткевич Г.Л., Маякова С.А. Лейкозы у детей. М.: Практическая медицина, 2009. 346 с.
    [Mentkevich GL, Mayakova SA. Leikozy u detei. (Leukemia in children.) Moscow: Prakticheskaya meditsina Publ.; 2009. 346 p. (In Russ)]
  2. Goto H. Childhood relapsed acute lymphoblastic leukemia: biology and recent treatment progress. Pediatr Intern. 2015;57(6):1059–66. doi: 10.1111/ped.12837.
  3. Pui CH, Carroll WL, Meshinchi S, Arceci R.J. Biology, risk stratification and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(36):551–65. doi: 10.1200/JCO.2010.30.7405.
  4. Pui CH, Evans EW. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2013;50(3):185–96. doi: 10.1053/j.seminhematol.2013.06.007.
  5. Bailey LC, Lange BJ, Rheingold SR, Bunin N.J. Bone-marrow relapse in pediatric acute lymphoblastic leukaemia. Lancet Oncol. 2008;9(9):873–83. doi: 10.1016/S1470-2045(08)70229-8.
  6. Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 2013;14(6):205–17. doi: 10.1016/S1470-2045(12)70580-6.
  7. Bhatla T. The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions. J Pediatr Hematol Oncol. 2014;36(6):413–8. doi: 10.1097/MPH.0000000000000179.
  8. Raetz AE, Bhatla T. Where do we stand in the treatment of relapsed acute lymphoblastic leukemia? Am Soc Hematol Educ Program. 2012;2012:129–36. doi: 10.1182/asheducation-2012.1.129.
  9. Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005;131(5):579–87. doi: 10.1111/j.1365-2141.2005.05773.x.
  10. MacKezie A, Kasner M. Therapeutic developments in acute lymphoblastic leukemia. Blood Lymph Cancer: Targets Ther. 2012;2:145–58. doi: 10.2147/BLCTT.S24990.
  11. Ko RH, Barnette P, Bostrom B, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia consortium study. J Clin Oncol. 2010;28(4):648–54. doi: 10.1200/JCO.2009.22.2950.
  12. Milano A, Perry F, Caponigro F. The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib. Onco Targets Ther. 2009;2:171–8. doi: 10.2147/OTT.S4503.
  13. Brown RE. Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia. Ann Clin Lab Sci. 2004;34(2):203–5.
  14. Du Xiao-Li, Chen Qi. Recent advancement of bortezomib in acute lymphoblastic leukemia treatment. Acta Haematol. 2013;129(4):207–14. doi: 10.1159/000345260.
  15. Horton TM. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006;58(13):13–23. doi: 10.1007/s00280-005-0135-z.
  16. Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010;55(2):254–9. doi: 10.1002/pbc.22456.
  17. Messinger YH, Gaynon PS, Sposto R, et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood. 2012;120(2):285–90. doi: 10.1182/blood-2012-04-418640.